Abstract
Treatment and control of schistosomiasis depends on a single drug, praziquantel, but this is not ideal for several reasons including lack of potency against the juvenile stage of the parasite, dose size, and risk of resistance. We have optimised the properties of a series of compounds we discovered through high throughput screening and have designed candidates for clinical development. The best compounds demonstrate clearance of both juvenile and adult S. mansoni worms in a mouse model of infection from a single oral dose of < 10 mg/kg. Several compounds in the series are predicted to treat schistosomiasis in humans across a range of species with a single oral dose of less than 5 mg/kg.
Publisher
Public Library of Science (PLoS)
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health
Reference33 articles.
1. WHO. Schistosomiasis 2020 [cited 2021 April 7]. Available from: https://www.who.int/news-room/fact-sheets/detail/schistosomiasis.
2. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa;MJ van der Werf;Acta tropica,2003
3. WHO schistosomiasis epidemiology 2018 [cited 2021 April 7]. Available from: http://www.who.int/schistosomiasis/epidemiology/table/en.
4. The unacknowledged impact of chronic schistosomiasis.;CH King;Chronic Illness,2008
5. The Schistosomiasis Control Initiative (SCI): rationale, development and implementation from 2002–2008.;A Fenwick;Parasitology,2009
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献